伊诺维奥制药公司（Inovio Pharmaceuticals）近日宣布，其公开发行方案已正式定价。该公司计划发行总计1250万股普通股，并附带购买同等数量普通股的认股权证，发行价格为每股1.40美元。
此次募股活动旨在为公司运营及管线开发注入新资金。发行条款显示，每股普通股将与一份认股权证一同发行，认股权证的行权价格等相关细节有待进一步披露。
市场正密切关注此次融资对伊诺维奥制药未来战略布局的影响。
伊诺维奥制药公司（Inovio Pharmaceuticals）近日宣布，其公开发行方案已正式定价。该公司计划发行总计1250万股普通股，并附带购买同等数量普通股的认股权证，发行价格为每股1.40美元。
此次募股活动旨在为公司运营及管线开发注入新资金。发行条款显示，每股普通股将与一份认股权证一同发行，认股权证的行权价格等相关细节有待进一步披露。
市场正密切关注此次融资对伊诺维奥制药未来战略布局的影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.